prof. MUDr. Jiří Ehrmann, Ph.D.

phone:

585 632 466

e-mail:

erman@tunw.upol.cz, jiri.ehrmann@tiscali.cz

 

Jiří EHRMANN, 2. 3. 1967. M.D. – LF UP, 1991; Ph.D. – LF UP, 2001; associate professor – LF UP, 2004; professor of pathology, 2007b

  1. Educational activity: continuous participation in education of pregraduate students. Management and organisation of pathology programme in dentistry branch. Management and organisation of pathology programme in english. Main author of 2 textbooks (1x for english students)
  2. Scientific education: tutor of 6 postgraduate students, member of commitees (Pathology and Forensic Medicine; Oncology) for postgraduate students in LF UP; member of commitee (Pathology and Forensic Medicine) for postgraduate students in LF UK Plzeň
  3. Scientific interests: prognostic/predictive pathology, apoptosis, quantitative pathology, oncogenes, nuclear receptors
  4. Scientific activity: principal investigator/co-investigator of 25 grant projects
  5. Publication activity: 56 original articles and reviews (16x in journal with IF ), 34 abstracts ans short communications (12x in journal with IF), main author of monography (Alkohol a játra, J.Ehrmann jr. P.Schneiderka, J.Ehrmann, Edice Malá monografie, Grada, 2006), 73 lectures and posters
  6. Citation: 235 citations
  7. Selected membership: member of commitee (secretary) of European Society of Pathology – Molecular Pathology Group, member of commitee of Section of diagnostic and predictive oncology of Czech oncology Society, member of commitee of Czech branch of International Academy of Pathology, member of commitee of Socitety of Histochemistry and Cytochemistry of Academy of Sciences, member of scientific board of Samantha Dickson Research Trust (UK)
  8. Most cited articles: Strakova N., Ehrmann J., Dzubak P, Bouchal J, Kolar Z. The synthetic ligand of PPARg ciglitazone, affects human glioblastoma cell lines. J Pharmacol Exp Ther 309, 2004, 1239-1247, (SCI-16x); Mokrý J, Čížková D, Filip S, Ehrmann J, Osterreicher J, Kolář Z, English D. Nestin expression by newly formed human blood vessels. Stem Cells Dev, 13, 2004, 658-664 (SCI-16x); Kolář Z., Murray P.G., Ehrmann J. jr., Flavell J.R., Rihaková P., Macak J., Lowe D., Crocker J., Vojtešek B., Young L.S. Apoptosis of malignant cells in Hodgkin´ s disease is related to expression of the Cdk inhibitor, p27 KIP1. J Pathol 190, 2000, 604-612, (SCI-20x); Ehrmann J. jr., Kolář Z., Vojtěšek B., Kala M, Komenda S., Oulton A. Prognostic factors in astrocytomas: Relationship of p53, MDM-2, BCL-2 and PCNA immunohistochemical expression to tumor grade and overall patient survival. Neoplasma 44, 1997, 23-28, (SCI-21x) ; Krajewski S., Krajewska M., Ehrmann J., Sikorska M., Lach B., Chatten J., Reed JC. Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1 and Bax in tumors of central and peripheral nervous system origin. Am J Pathol 150, 1997, 805-814, (SCI-92x);
  9. Scientific activity: 2003-2007 28 original articles and reviews (7x in journal with IF); 10 grant projects (investigator/co-investigator) – 9x registered in CEP